Topical Pain Relief Market by Therapeutic Class (Non-Opioids and Opioids), Formulation (Cream, Gel, Spray, Patch, and Others), Type (Prescription Pain Relief and Over-the-Counter Pain Relief), and Distribution Channel (Pharmacies & Drug Stores, E-Commerce, and Retail & Grocery Stores): Global Opportunity Analysis and Industry Forecast, 2020–2027
The global topical pain relief market was valued at $8,864.0 million in 2019, and is projected to reach $12,219.7 million by 2027 at a CAGR of 5.2% from 2020 to 2027.
Pain treatment involves usage of common analgesics or painkillers to reduce and treat body pain. Whenever, these analgesics are applied directly to the skin they are known as topical pain relief medications. These include topical administration of drugs such as non-steroidal anti-inflammatory drugs, anesthetics, capsaicin, tricyclic antidepressants, ketamine, clonidine, opioids, and cannabinoids. Topical pain relief medications exert peripheral effects near the site of application and minimize the pain. Topical formulations used for pain relief include creams, ointments, gels, and newly developed drug-delivery systems, usually transdermal patches. They are mostly available as over-the-counter (OTC) products while some are available through prescription only.
Increase in prevalence of arthritis is the major factor that contributes toward the growth of the topical pain relief market. Moreover, other factors that fuel the market growth include surge in geriatric population, lesser side effects caused due to use of topical analgesics as compared to oral pain relief, wide availability of topical pain-relieving drugs, and high demand for topical pain relief by sports players. However, topical pain relief medications can cause irritated skin and they have a strong odor or unpleasant smell that impede the market growth. Conversely, development of online platform for the topical therapeutics and high market potential in untapped emerging economies are expected to provide lucrative opportunities for the growth of the market.
The global topical pain relief market is segmented into therapeutic class, type, formulation, distribution channel, and region. By therapeutic class, the market is bifurcated into non-opioids and opioids. The non-opioids segment is further divided into nonsteroidal anti-inflammatory drugs (NSAIDS), methyl salicylate, capsaicin, lidocaine, and other non-opioids. The opioids segment is further bifurcated into buprenorphine and fentanyl. By type, the market is segmented into prescription pain relief and over-the-counter (OTC) relief. By formulation, the market is classified into cream, gel, spray, patch, and others. The distribution channels covered in the study include Pharmacies & drug stores, e-commerce, and retail & grocery stores. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The report provides an extensive competitive analysis and profiles of the key market players such as AdvaCare Pharma, GlaxoSmithKline plc (GSK), Johnson & Johnson, Nestl? S.A., Novartis AG, Pfizer Inc., Reckitt Benckiser Group plc, Sanofi S.A., Sun Pharmaceutical Industries Ltd. And Topical BioMedics, Inc.
KEY BENEFITS FOR STAKEHOLDERS
By Therapeutic Class
Pain treatment involves usage of common analgesics or painkillers to reduce and treat body pain. Whenever, these analgesics are applied directly to the skin they are known as topical pain relief medications. These include topical administration of drugs such as non-steroidal anti-inflammatory drugs, anesthetics, capsaicin, tricyclic antidepressants, ketamine, clonidine, opioids, and cannabinoids. Topical pain relief medications exert peripheral effects near the site of application and minimize the pain. Topical formulations used for pain relief include creams, ointments, gels, and newly developed drug-delivery systems, usually transdermal patches. They are mostly available as over-the-counter (OTC) products while some are available through prescription only.
Increase in prevalence of arthritis is the major factor that contributes toward the growth of the topical pain relief market. Moreover, other factors that fuel the market growth include surge in geriatric population, lesser side effects caused due to use of topical analgesics as compared to oral pain relief, wide availability of topical pain-relieving drugs, and high demand for topical pain relief by sports players. However, topical pain relief medications can cause irritated skin and they have a strong odor or unpleasant smell that impede the market growth. Conversely, development of online platform for the topical therapeutics and high market potential in untapped emerging economies are expected to provide lucrative opportunities for the growth of the market.
The global topical pain relief market is segmented into therapeutic class, type, formulation, distribution channel, and region. By therapeutic class, the market is bifurcated into non-opioids and opioids. The non-opioids segment is further divided into nonsteroidal anti-inflammatory drugs (NSAIDS), methyl salicylate, capsaicin, lidocaine, and other non-opioids. The opioids segment is further bifurcated into buprenorphine and fentanyl. By type, the market is segmented into prescription pain relief and over-the-counter (OTC) relief. By formulation, the market is classified into cream, gel, spray, patch, and others. The distribution channels covered in the study include Pharmacies & drug stores, e-commerce, and retail & grocery stores. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The report provides an extensive competitive analysis and profiles of the key market players such as AdvaCare Pharma, GlaxoSmithKline plc (GSK), Johnson & Johnson, Nestl? S.A., Novartis AG, Pfizer Inc., Reckitt Benckiser Group plc, Sanofi S.A., Sun Pharmaceutical Industries Ltd. And Topical BioMedics, Inc.
KEY BENEFITS FOR STAKEHOLDERS
- The study presents an in-depth analysis of the global topical pain relief market along with the current trends and future estimations from 2019 to 2027 to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided.
- Identification of factors instrumental in changing the market scenario, rise in opportunities, and recognition of the key players that can influence this market on a global & regional scale are provided in the report.
- Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
By Therapeutic Class
- Non-opioids
- Nonsteroidal anti-inflammatory drug (NSAIDS)
- Methyl Salicylate
- Capsaicin
- Lidocaine
- Other Non-opioids
- Opioids
- Buprenorphine
- Fentanyl
- Cream
- Gel
- Spray
- Patch
- Others
- Prescription Pain Relief
- Over-the-counter (OTC) Pain Relief
- Pharmacy & Drug Store
- e-Commerce
- Retail & Grocery Store
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- AdvaCare Pharma
- GlaxoSmithKline plc (GSK)
- Johnson & Johnson
- Nestl? S.A.
- Novartis AG
- Pfizer Inc.
- Reckitt Benckiser Group plc
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
- Topical BioMedics, Inc.
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Top player positioning
3.4.Porter’s five force analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in prevalence of arthritis
3.5.1.2.Growth in geriatric population
3.5.1.3.High demand for topical pain relief products by sportsperson
3.5.1.4.Lesser side effects caused by topical pain relief products as
compared to oral medicines
3.5.2.Restraints
3.5.2.1.Topical pain relief sometimes cause skin irritants
3.5.2.2.Topical pain relief is characterized by unpleasant odor
3.5.3.Opportunities
3.5.3.1.Emergence of online pharmacy
3.5.3.2.Opportunities in emerging economies
3.5.4.Impact analysis
3.6.COVID-19 Impact analysis on global topical pain relief market
CHAPTER 4:GLOBAL TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC
CLASS
4.1.Overview
4.1.1.Market size and forecast
4.2.Non-opioids
4.2.1.Key market trends, growth factors and opportunities
4.2.2.Market size and forecast, by type
4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country
4.2.4.1.Nonsteroidal anti-inflammatory drugs (NSAIDS)
4.2.4.2.Methyl salicylates
4.2.4.3.Capsaicin
4.2.4.4.Lidocaine
4.2.4.5.Other non-opioids
4.3.Opioids
4.3.1.Key market trends, growth factors and opportunities
4.3.2.Market size and forecast, by type
4.3.3.Market size and forecast, by region
4.3.4.Market analysis, by country
4.3.4.1.Buprenorphine
4.3.4.2.Fentanyl
CHAPTER 5:GLOBAL TOPICAL PAIN RELIEF MARKET, BY FORMULATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Cream
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Gel
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Spray
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Patch
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Others
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
CHAPTER 6:GLOABL. TOPICAL PAIN RELIEF MARKET, BY TYPE
6.1.Overview
6.1.1.Market size and forecast
6.2.Prescription pain relief
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Over-the-counter pain relief
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
CHAPTER 7:GLOBAL TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL
7.1.Overview
7.1.1.Market size and forecast
7.2.Pharmacies & drug stores
7.2.1.Market size and forecast, by region
7.2.2.Market analysis, by country
7.3.E-Commerce
7.3.1.Market size and forecast, by region
7.3.2.Market analysis, by country
7.4.Retail & grocery stores
7.4.1.Market size and forecast, by region
7.4.2.Market analysis, by country
CHAPTER 8:TOPICAL PAIN RELIEF MARKET, BY REGION
8.1.Overview
8.1.1.Market size and forecast
8.2.North America
8.2.1.Key market trends, growth factors and opportunities
8.2.2.North America topical pain relief market, by country
8.2.2.1.U.S. topical pain relief market, by therapeutic class
8.2.2.2.U.S. topical pain relief market, by formulation
8.2.2.3.U.S. topical pain relief market, by type
8.2.2.4.U.S. topical pain relief market, by distribution channel
8.2.2.5.Canada topical pain relief market, by therapeutic class
8.2.2.6.Canada topical pain relief market, by formulation
8.2.2.7.Canada topical pain relief market, by type
8.2.2.8.Canada topical pain relief market, by distribution channel
8.2.2.9.Mexico topical pain relief market, by therapeutic class
8.2.2.10.Mexico topical pain relief market, by formulation
8.2.2.11.Mexico topical pain relief market, by type
8.2.2.12.Mexico topical pain relief market, by distribution channel
8.2.3.North America market size and forecast, by therapeutic class
8.2.4.North America market size and forecast, by formulation
8.2.5.North America market size and forecast, by type
8.2.6.North America market size and forecast, by distribution channel
8.3.Europe
8.3.1.Key market trends, growth factors and opportunities
8.3.2.Europe market size and forecast, by country
8.3.2.1.Germany topical pain relief market, by therapeutic class
8.3.2.2.Germany topical pain relief market, by formulation
8.3.2.3.Germany topical pain relief market, by type
8.3.2.4.Germany topical pain relief market, by distribution channel
8.3.2.5.France topical pain relief market, by therapeutic class
8.3.2.6.France topical pain relief market, by formulation
8.3.2.7.France topical pain relief market, by type
8.3.2.8.France topical pain relief market, by distribution channel
8.3.2.9.UK topical pain relief market, by therapeutic class
8.3.2.10.U.K. topical pain relief market, by formulation
8.3.2.11.UK topical pain relief market, by type
8.3.2.12.UK topical pain relief market, by distribution channel
8.3.2.13.Italy topical pain relief market, by therapeutic class
8.3.2.14.Italy topical pain relief market, by formulation
8.3.2.15.Italy topical pain relief market, by type
8.3.2.16.Italy topical pain relief market, by distribution channel
8.3.2.17.Spain topical pain relief market, by therapeutic class
8.3.2.18.Spain topical pain relief market, by formulation
8.3.2.19.Spain topical pain relief market, by type
8.3.2.20.Spain topical pain relief market, by distribution channel
8.3.2.21.Rest of Europe topical pain relief market, by therapeutic class
8.3.2.22.Rest of Europe topical pain relief market, by formulation
8.3.2.23.Rest of Europe topical pain relief market, by type
8.3.2.24.Rest of Europe topical pain relief market, by distribution channel
8.3.3.Europe market size and forecast, by therapeutic class
8.3.4.Europe market size and forecast, by formulation
8.3.5.Europe market size and forecast, by type
8.3.6.Europe market size and forecast, by distribution channel
8.4.Asia-Pacific
8.4.1.Key market trends, growth factors and opportunities
8.4.2.Asia-Pacific market size and forecast, by country
8.4.2.1.China topical pain relief market, by therapeutic class
8.4.2.2.China topical pain relief market, by formulation
8.4.2.3.China topical pain relief market, by type
8.4.2.4.China topical pain relief market, by distribution channel
8.4.2.5.Japan topical pain relief market, by therapeutic class
8.4.2.6.Japan topical pain relief market, by formulation
8.4.2.7.Japan topical pain relief market, by type
8.4.2.8.Japan topical pain relief market, by distribution channel
8.4.2.9.India topical pain relief market, by therapeutic class
8.4.2.10.India topical pain relief market, by formulation
8.4.2.11.India topical pain relief market, by type
8.4.2.12.India topical pain relief market, by distribution channel
8.4.2.13.Australia topical pain relief market, by therapeutic class
8.4.2.14.Australia topical pain relief market, by formulation
8.4.2.15.Australia topical pain relief market, by type
8.4.2.16.Australia topical pain relief market, by distribution channel
8.4.2.17.South Korea topical pain relief market, by therapeutic class
8.4.2.18.South Korea topical pain relief market, by formulation
8.4.2.19.South Korea topical pain relief market, by type
8.4.2.20.South Korea topical pain relief market, by distribution channel
8.4.2.21.Rest of Asia-Pacific topical pain relief market, by therapeutic class
8.4.2.22.Rest of Asia-Pacific topical pain relief market, by formulation
8.4.2.23.Rest of Asia- Pacific topical pain relief market, by type
8.4.2.24.Rest of Asia- Pacific topical pain relief market,
by distribution channel
8.4.3.Asia-Pacific market size and forecast, by therapeutic class
8.4.4.Asia-Pacific market size and forecast, by formulation
8.4.5.Asia-Pacific market size and forecast, by type
8.4.6.Asia-Pacific market size and forecast, by distribution channel
8.5.LAMEA
8.5.1.Key market trends, growth factors and opportunities
8.5.2.LAMEA market size and forecast, by country
8.5.2.1.Brazil topical pain relief market, by therapeutic class
8.5.2.2.Brazil topical pain relief market, by formulation
8.5.2.3.Brazil topical pain relief market, by type
8.5.2.4.Brazil topical pain relief market, by distribution channel
8.5.2.5.Saudi Arabia topical pain relief market, by therapeutic class
8.5.2.6.Saudi Arabia topical pain relief market, by formulation
8.5.2.7.Saudi Arabia topical pain relief market, by type
8.5.2.8.Saudi Arabia topical pain relief market, by distribution channel
8.5.2.9.South Africa topical pain relief market, by therapeutic class
8.5.2.10.South Africa topical pain relief market, by formulation
8.5.2.11.South Africa topical pain relief market, by type
8.5.2.12.South Africa topical pain relief market, by distribution channel
8.5.2.13.Rest of LAMEA topical pain relief market, by therapeutic class
8.5.2.14.Rest of LAMEA South Africa topical pain relief market, by formulation
8.5.2.15.Rest of LAMEA topical pain relief market, by type
8.5.2.16.Rest of LAMEA topical pain relief market, by distribution channel
8.5.3.LAMEA market size and forecast, by therapeutic class
8.5.4.LAMEA market size and forecast, by formulation
8.5.5.LAMEA market size and forecast, by type
8.5.6.LAMEA market size and forecast, by distribution channel
CHAPTER 9:COMPANY PROFILES
9.1.ADVACARE PHARMA
9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product Portfolio
9.2.GLAXOSMITHKLINE PLC (GSK)
9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
9.2.5.Business performance
9.2.6.Key strategic moves and developments
9.3.JOHNSON & JOHNSON
9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Business performance
9.4.NESTL? S.A.
9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product Portfolio
9.4.5.Business performance
9.5.NOVARTIS AG
9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Business performance
9.6.PFIZER INC.
9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Business performance
9.7.RECKITT BENCKISER GROUP PLC
9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product Portfolio
9.7.5.Business performance
9.8.SANOFI
9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance
9.9.SUN PHARMACEUTICAL INDUSTRIES LTD.
9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance
9.10.TOPICAL BIOMEDICS, INC.
9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product Portfolio
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Top player positioning
3.4.Porter’s five force analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in prevalence of arthritis
3.5.1.2.Growth in geriatric population
3.5.1.3.High demand for topical pain relief products by sportsperson
3.5.1.4.Lesser side effects caused by topical pain relief products as
compared to oral medicines
3.5.2.Restraints
3.5.2.1.Topical pain relief sometimes cause skin irritants
3.5.2.2.Topical pain relief is characterized by unpleasant odor
3.5.3.Opportunities
3.5.3.1.Emergence of online pharmacy
3.5.3.2.Opportunities in emerging economies
3.5.4.Impact analysis
3.6.COVID-19 Impact analysis on global topical pain relief market
CHAPTER 4:GLOBAL TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC
CLASS
4.1.Overview
4.1.1.Market size and forecast
4.2.Non-opioids
4.2.1.Key market trends, growth factors and opportunities
4.2.2.Market size and forecast, by type
4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country
4.2.4.1.Nonsteroidal anti-inflammatory drugs (NSAIDS)
4.2.4.2.Methyl salicylates
4.2.4.3.Capsaicin
4.2.4.4.Lidocaine
4.2.4.5.Other non-opioids
4.3.Opioids
4.3.1.Key market trends, growth factors and opportunities
4.3.2.Market size and forecast, by type
4.3.3.Market size and forecast, by region
4.3.4.Market analysis, by country
4.3.4.1.Buprenorphine
4.3.4.2.Fentanyl
CHAPTER 5:GLOBAL TOPICAL PAIN RELIEF MARKET, BY FORMULATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Cream
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Gel
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Spray
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Patch
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Others
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
CHAPTER 6:GLOABL. TOPICAL PAIN RELIEF MARKET, BY TYPE
6.1.Overview
6.1.1.Market size and forecast
6.2.Prescription pain relief
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Over-the-counter pain relief
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
CHAPTER 7:GLOBAL TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL
7.1.Overview
7.1.1.Market size and forecast
7.2.Pharmacies & drug stores
7.2.1.Market size and forecast, by region
7.2.2.Market analysis, by country
7.3.E-Commerce
7.3.1.Market size and forecast, by region
7.3.2.Market analysis, by country
7.4.Retail & grocery stores
7.4.1.Market size and forecast, by region
7.4.2.Market analysis, by country
CHAPTER 8:TOPICAL PAIN RELIEF MARKET, BY REGION
8.1.Overview
8.1.1.Market size and forecast
8.2.North America
8.2.1.Key market trends, growth factors and opportunities
8.2.2.North America topical pain relief market, by country
8.2.2.1.U.S. topical pain relief market, by therapeutic class
8.2.2.2.U.S. topical pain relief market, by formulation
8.2.2.3.U.S. topical pain relief market, by type
8.2.2.4.U.S. topical pain relief market, by distribution channel
8.2.2.5.Canada topical pain relief market, by therapeutic class
8.2.2.6.Canada topical pain relief market, by formulation
8.2.2.7.Canada topical pain relief market, by type
8.2.2.8.Canada topical pain relief market, by distribution channel
8.2.2.9.Mexico topical pain relief market, by therapeutic class
8.2.2.10.Mexico topical pain relief market, by formulation
8.2.2.11.Mexico topical pain relief market, by type
8.2.2.12.Mexico topical pain relief market, by distribution channel
8.2.3.North America market size and forecast, by therapeutic class
8.2.4.North America market size and forecast, by formulation
8.2.5.North America market size and forecast, by type
8.2.6.North America market size and forecast, by distribution channel
8.3.Europe
8.3.1.Key market trends, growth factors and opportunities
8.3.2.Europe market size and forecast, by country
8.3.2.1.Germany topical pain relief market, by therapeutic class
8.3.2.2.Germany topical pain relief market, by formulation
8.3.2.3.Germany topical pain relief market, by type
8.3.2.4.Germany topical pain relief market, by distribution channel
8.3.2.5.France topical pain relief market, by therapeutic class
8.3.2.6.France topical pain relief market, by formulation
8.3.2.7.France topical pain relief market, by type
8.3.2.8.France topical pain relief market, by distribution channel
8.3.2.9.UK topical pain relief market, by therapeutic class
8.3.2.10.U.K. topical pain relief market, by formulation
8.3.2.11.UK topical pain relief market, by type
8.3.2.12.UK topical pain relief market, by distribution channel
8.3.2.13.Italy topical pain relief market, by therapeutic class
8.3.2.14.Italy topical pain relief market, by formulation
8.3.2.15.Italy topical pain relief market, by type
8.3.2.16.Italy topical pain relief market, by distribution channel
8.3.2.17.Spain topical pain relief market, by therapeutic class
8.3.2.18.Spain topical pain relief market, by formulation
8.3.2.19.Spain topical pain relief market, by type
8.3.2.20.Spain topical pain relief market, by distribution channel
8.3.2.21.Rest of Europe topical pain relief market, by therapeutic class
8.3.2.22.Rest of Europe topical pain relief market, by formulation
8.3.2.23.Rest of Europe topical pain relief market, by type
8.3.2.24.Rest of Europe topical pain relief market, by distribution channel
8.3.3.Europe market size and forecast, by therapeutic class
8.3.4.Europe market size and forecast, by formulation
8.3.5.Europe market size and forecast, by type
8.3.6.Europe market size and forecast, by distribution channel
8.4.Asia-Pacific
8.4.1.Key market trends, growth factors and opportunities
8.4.2.Asia-Pacific market size and forecast, by country
8.4.2.1.China topical pain relief market, by therapeutic class
8.4.2.2.China topical pain relief market, by formulation
8.4.2.3.China topical pain relief market, by type
8.4.2.4.China topical pain relief market, by distribution channel
8.4.2.5.Japan topical pain relief market, by therapeutic class
8.4.2.6.Japan topical pain relief market, by formulation
8.4.2.7.Japan topical pain relief market, by type
8.4.2.8.Japan topical pain relief market, by distribution channel
8.4.2.9.India topical pain relief market, by therapeutic class
8.4.2.10.India topical pain relief market, by formulation
8.4.2.11.India topical pain relief market, by type
8.4.2.12.India topical pain relief market, by distribution channel
8.4.2.13.Australia topical pain relief market, by therapeutic class
8.4.2.14.Australia topical pain relief market, by formulation
8.4.2.15.Australia topical pain relief market, by type
8.4.2.16.Australia topical pain relief market, by distribution channel
8.4.2.17.South Korea topical pain relief market, by therapeutic class
8.4.2.18.South Korea topical pain relief market, by formulation
8.4.2.19.South Korea topical pain relief market, by type
8.4.2.20.South Korea topical pain relief market, by distribution channel
8.4.2.21.Rest of Asia-Pacific topical pain relief market, by therapeutic class
8.4.2.22.Rest of Asia-Pacific topical pain relief market, by formulation
8.4.2.23.Rest of Asia- Pacific topical pain relief market, by type
8.4.2.24.Rest of Asia- Pacific topical pain relief market,
by distribution channel
8.4.3.Asia-Pacific market size and forecast, by therapeutic class
8.4.4.Asia-Pacific market size and forecast, by formulation
8.4.5.Asia-Pacific market size and forecast, by type
8.4.6.Asia-Pacific market size and forecast, by distribution channel
8.5.LAMEA
8.5.1.Key market trends, growth factors and opportunities
8.5.2.LAMEA market size and forecast, by country
8.5.2.1.Brazil topical pain relief market, by therapeutic class
8.5.2.2.Brazil topical pain relief market, by formulation
8.5.2.3.Brazil topical pain relief market, by type
8.5.2.4.Brazil topical pain relief market, by distribution channel
8.5.2.5.Saudi Arabia topical pain relief market, by therapeutic class
8.5.2.6.Saudi Arabia topical pain relief market, by formulation
8.5.2.7.Saudi Arabia topical pain relief market, by type
8.5.2.8.Saudi Arabia topical pain relief market, by distribution channel
8.5.2.9.South Africa topical pain relief market, by therapeutic class
8.5.2.10.South Africa topical pain relief market, by formulation
8.5.2.11.South Africa topical pain relief market, by type
8.5.2.12.South Africa topical pain relief market, by distribution channel
8.5.2.13.Rest of LAMEA topical pain relief market, by therapeutic class
8.5.2.14.Rest of LAMEA South Africa topical pain relief market, by formulation
8.5.2.15.Rest of LAMEA topical pain relief market, by type
8.5.2.16.Rest of LAMEA topical pain relief market, by distribution channel
8.5.3.LAMEA market size and forecast, by therapeutic class
8.5.4.LAMEA market size and forecast, by formulation
8.5.5.LAMEA market size and forecast, by type
8.5.6.LAMEA market size and forecast, by distribution channel
CHAPTER 9:COMPANY PROFILES
9.1.ADVACARE PHARMA
9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product Portfolio
9.2.GLAXOSMITHKLINE PLC (GSK)
9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
9.2.5.Business performance
9.2.6.Key strategic moves and developments
9.3.JOHNSON & JOHNSON
9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Business performance
9.4.NESTL? S.A.
9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product Portfolio
9.4.5.Business performance
9.5.NOVARTIS AG
9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Business performance
9.6.PFIZER INC.
9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Business performance
9.7.RECKITT BENCKISER GROUP PLC
9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product Portfolio
9.7.5.Business performance
9.8.SANOFI
9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance
9.9.SUN PHARMACEUTICAL INDUSTRIES LTD.
9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance
9.10.TOPICAL BIOMEDICS, INC.
9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product Portfolio
LIST OF TABLES
TABLE 01.GLOBAL TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 02.GLOBAL TOPICAL NON-OPIOIDS MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 03.TOPICAL NON-OPIOIDS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 04.GLOBAL TOPICAL OPIOIDS MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 05.TOPICAL OPIOIDS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 06.GLOBAL TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 07.TOPICAL PAIN RELIEF MARKET FOR CREAM, BY REGION, 2019–2027 ($MILLION)
TABLE 08.TOPICAL PAIN RELIEF MARKET FOR GEL, BY REGION, 2019–2027 ($MILLION)
TABLE 09.TOPICAL PAIN RELIEF MARKET FOR SPRAY, BY REGION, 2019–2027 ($MILLION)
TABLE 10.TOPICAL PAIN RELIEF MARKET FOR PATCH, BY REGION, 2019–2027 ($MILLION)
TABLE 11.TOPICAL PAIN RELIEF MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 12.GLOBAL TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 13.PRESCRIPTION TOPICAL PAIN RELIEF MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 14.OVER-THE-COUNTER TOPICAL PAIN RELIEF MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 15.GLOBAL TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 16.TOPICAL PAIN RELIEF MARKET FOR PHARMACIES & DRUG STORES, BY REGION,
2019–2027 ($MILLION)
TABLE 17.TOPICAL PAIN RELIEF MARKET FOR E-COMMERCE, BY REGION, 2019–2027 ($MILLION)
TABLE 18.GLOBAL TOPICAL PAIN RELIEF MARKET FOR REATIL & GROCERY SHOPS, BY REGION,
2017–2025 ($MILLION)
TABLE 19.GLOBAL TOPICAL PAIN RELIEF MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 20.NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 21.U.S. TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 22.U.S. TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 23.U.S. TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 24.U.S. TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 25.CANADA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 26.CANADA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 27.CANADA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 28.CANADA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 29.MEXICO TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 30.MEXICO TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 31.MEXICO TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 32.MEXICO TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 33.NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
TABLE 34.NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019-2027 ($MILLION)
TABLE 35.NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 36.NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 37.EUROPE TOPICAL PAIN RELIEF MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 38.GERMANY TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 39.GERMANY TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 40.GERMANY TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 41.GERMANY TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 42.FRANCE TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 43.FRANCE TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 44.FRANCE TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 45.FRANCE TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 46.UK TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 47.U.K. TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017–2027 ($MILLION)
TABLE 48.UK TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 49.UK TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 50.ITALY TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 51.ITALY TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 52.ITALY TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 53.ITALY TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 54.SPAIN TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 55.SPAIN TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 56.SPAIN TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 57.SPAIN TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 58.REST OF EUROPE TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 59.REST OF EUROPE TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 60.REST OF EUROPE TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 61.REST OF EUROPE TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL,
2019–2027 ($MILLION)
TABLE 62.EUROPE TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
TABLE 63.EUROPE TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019-2027 ($MILLION)
TABLE 64.EUROPE TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 65.EUROPE TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 66.ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 67.CHINA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 68.CHINA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 69.CHINA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 70.CHINA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 71.JAPAN TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 72.JAPAN TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 73.JAPAN TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 74.JAPAN TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 75.INDIA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 76.INDIA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 77.INDIA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 78.INDIA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 79.AUSTRALIA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 80.AUSTRALIA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 81.AUSTRALIA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 82.AUSTRALIA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 83.SOUTH KOREA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 84.SOUTH KOREA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 85.SOUTH KOREA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 86.SOUTH KOREA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 87.REST OF ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS,
2019–2027 ($MILLION)
TABLE 88.REST OF ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 89.REST OF ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 90.REST OF ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL,
2019–2027 ($MILLION)
TABLE 91.ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 92.ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019-2027 ($MILLION)
TABLE 93.ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 94.ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 95.LAMEA TOPICAL PAIN RELIEF MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 96.BRAZIL TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 97.BRAZIL TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 98.BRAZIL TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 99.BRAZIL TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 100.SAUDI ARABIA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 101.SAUDI ARABIA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 102.SAUDI ARABIA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 103.SAUDI ARABIA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 104.SOUTH AFRICA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 105.SOUTH AFRICA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 106.SOUTH ARICA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 107.SOUTH ARICA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 108.REST OF LAMEA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 109.REST OF LAMEA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 110.REST OF LAMEA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 111.REST OF LAMEA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 112.LAMEA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 113.LAMEA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019-2027 ($MILLION)
TABLE 114.LAMEA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 115.LAMEA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 116.ADVACARE: COMPANY SNAPSHOT
TABLE 117.ADVACARE: BUSINESS SEGMENTS
TABLE 118.ADVACARE: PRODUCT PORTFOLIO
TABLE 119.GSK: COMPANY SNAPSHOT
TABLE 120.GLAXOSMITHKLINE PLC.: OPERATING SEGMENT
TABLE 121.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 122.GSK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 123.J&J: COMPANY SNAPSHOT
TABLE 124.J&J: OPERATING SEGMENTS
TABLE 125.J&J: PRODUCT PORTFOLIO
TABLE 126.NESTL?: COMPANY SNAPSHOT
TABLE 127.NESTL?: OPERATING SEGMENTS
TABLE 128.NESTL?: PRODUCT PORTFOLIO
TABLE 129.NOVARTIS: COMPANY SNAPSHOT
TABLE 130.NOVARTIS: OPERATING SEGMENT
TABLE 131.NOVARTIS: PRODUCT PORTFOLIO
TABLE 132.PFIZER: COMPANY SNAPSHOT
TABLE 133.PFIZER: OPERATING SEGMENT
TABLE 134.PFIZER: PRODUCT PORTFOLIO
TABLE 135.RB: COMPANY SNAPSHOT
TABLE 136.RB: OPERATING SEGMENTS
TABLE 137.RB: PRODUCT PORTFOLIO
TABLE 138.SANOFI: COMPANY SNAPSHOT
TABLE 139.SANOFI: OPERATING SEGMENT
TABLE 140.SANOFI: PRODUCT PORTFOLIO
TABLE 141.SUN PHARMA: COMPANY SNAPSHOT
TABLE 142.SUN PHARMA: OPERATING SEGMENTS
TABLE 143.SUN PHARMA: PRODUCT PORTFOLIO
TABLE 144.TOPICAL BIOMEDICS: COMPANY SNAPSHOT
TABLE 145.TOPICAL BIOMEDICS: OPERATING SEGMENTS
TABLE 146.TOPICAL BIOMEDICS: PRODUCT PORTFOLIO
TABLE 01.GLOBAL TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 02.GLOBAL TOPICAL NON-OPIOIDS MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 03.TOPICAL NON-OPIOIDS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 04.GLOBAL TOPICAL OPIOIDS MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 05.TOPICAL OPIOIDS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 06.GLOBAL TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 07.TOPICAL PAIN RELIEF MARKET FOR CREAM, BY REGION, 2019–2027 ($MILLION)
TABLE 08.TOPICAL PAIN RELIEF MARKET FOR GEL, BY REGION, 2019–2027 ($MILLION)
TABLE 09.TOPICAL PAIN RELIEF MARKET FOR SPRAY, BY REGION, 2019–2027 ($MILLION)
TABLE 10.TOPICAL PAIN RELIEF MARKET FOR PATCH, BY REGION, 2019–2027 ($MILLION)
TABLE 11.TOPICAL PAIN RELIEF MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 12.GLOBAL TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 13.PRESCRIPTION TOPICAL PAIN RELIEF MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 14.OVER-THE-COUNTER TOPICAL PAIN RELIEF MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 15.GLOBAL TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 16.TOPICAL PAIN RELIEF MARKET FOR PHARMACIES & DRUG STORES, BY REGION,
2019–2027 ($MILLION)
TABLE 17.TOPICAL PAIN RELIEF MARKET FOR E-COMMERCE, BY REGION, 2019–2027 ($MILLION)
TABLE 18.GLOBAL TOPICAL PAIN RELIEF MARKET FOR REATIL & GROCERY SHOPS, BY REGION,
2017–2025 ($MILLION)
TABLE 19.GLOBAL TOPICAL PAIN RELIEF MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 20.NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 21.U.S. TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 22.U.S. TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 23.U.S. TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 24.U.S. TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 25.CANADA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 26.CANADA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 27.CANADA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 28.CANADA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 29.MEXICO TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 30.MEXICO TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 31.MEXICO TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 32.MEXICO TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 33.NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
TABLE 34.NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019-2027 ($MILLION)
TABLE 35.NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 36.NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 37.EUROPE TOPICAL PAIN RELIEF MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 38.GERMANY TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 39.GERMANY TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 40.GERMANY TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 41.GERMANY TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 42.FRANCE TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 43.FRANCE TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 44.FRANCE TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 45.FRANCE TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 46.UK TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 47.U.K. TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017–2027 ($MILLION)
TABLE 48.UK TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 49.UK TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 50.ITALY TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 51.ITALY TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 52.ITALY TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 53.ITALY TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 54.SPAIN TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 55.SPAIN TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 56.SPAIN TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 57.SPAIN TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 58.REST OF EUROPE TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 59.REST OF EUROPE TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 60.REST OF EUROPE TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 61.REST OF EUROPE TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL,
2019–2027 ($MILLION)
TABLE 62.EUROPE TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
TABLE 63.EUROPE TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019-2027 ($MILLION)
TABLE 64.EUROPE TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 65.EUROPE TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 66.ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 67.CHINA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 68.CHINA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 69.CHINA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 70.CHINA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 71.JAPAN TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 72.JAPAN TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 73.JAPAN TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 74.JAPAN TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 75.INDIA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 76.INDIA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 77.INDIA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 78.INDIA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 79.AUSTRALIA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 80.AUSTRALIA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 81.AUSTRALIA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 82.AUSTRALIA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 83.SOUTH KOREA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 84.SOUTH KOREA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 85.SOUTH KOREA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 86.SOUTH KOREA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 87.REST OF ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS,
2019–2027 ($MILLION)
TABLE 88.REST OF ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 89.REST OF ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 90.REST OF ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL,
2019–2027 ($MILLION)
TABLE 91.ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 92.ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019-2027 ($MILLION)
TABLE 93.ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 94.ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 95.LAMEA TOPICAL PAIN RELIEF MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 96.BRAZIL TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 97.BRAZIL TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 98.BRAZIL TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 99.BRAZIL TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 100.SAUDI ARABIA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 101.SAUDI ARABIA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 102.SAUDI ARABIA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 103.SAUDI ARABIA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 104.SOUTH AFRICA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 105.SOUTH AFRICA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 106.SOUTH ARICA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 107.SOUTH ARICA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 108.REST OF LAMEA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 109.REST OF LAMEA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 110.REST OF LAMEA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 111.REST OF LAMEA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 112.LAMEA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 113.LAMEA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019-2027 ($MILLION)
TABLE 114.LAMEA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 115.LAMEA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 116.ADVACARE: COMPANY SNAPSHOT
TABLE 117.ADVACARE: BUSINESS SEGMENTS
TABLE 118.ADVACARE: PRODUCT PORTFOLIO
TABLE 119.GSK: COMPANY SNAPSHOT
TABLE 120.GLAXOSMITHKLINE PLC.: OPERATING SEGMENT
TABLE 121.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 122.GSK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 123.J&J: COMPANY SNAPSHOT
TABLE 124.J&J: OPERATING SEGMENTS
TABLE 125.J&J: PRODUCT PORTFOLIO
TABLE 126.NESTL?: COMPANY SNAPSHOT
TABLE 127.NESTL?: OPERATING SEGMENTS
TABLE 128.NESTL?: PRODUCT PORTFOLIO
TABLE 129.NOVARTIS: COMPANY SNAPSHOT
TABLE 130.NOVARTIS: OPERATING SEGMENT
TABLE 131.NOVARTIS: PRODUCT PORTFOLIO
TABLE 132.PFIZER: COMPANY SNAPSHOT
TABLE 133.PFIZER: OPERATING SEGMENT
TABLE 134.PFIZER: PRODUCT PORTFOLIO
TABLE 135.RB: COMPANY SNAPSHOT
TABLE 136.RB: OPERATING SEGMENTS
TABLE 137.RB: PRODUCT PORTFOLIO
TABLE 138.SANOFI: COMPANY SNAPSHOT
TABLE 139.SANOFI: OPERATING SEGMENT
TABLE 140.SANOFI: PRODUCT PORTFOLIO
TABLE 141.SUN PHARMA: COMPANY SNAPSHOT
TABLE 142.SUN PHARMA: OPERATING SEGMENTS
TABLE 143.SUN PHARMA: PRODUCT PORTFOLIO
TABLE 144.TOPICAL BIOMEDICS: COMPANY SNAPSHOT
TABLE 145.TOPICAL BIOMEDICS: OPERATING SEGMENTS
TABLE 146.TOPICAL BIOMEDICS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.GLOBAL TOPICAL PAIN RELIEF MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04.HIGH BARGAINING POWER OF BUYERS
FIGURE 05.HIGH THREAT OF SUBSTITUTES
FIGURE 06.HIGH THREAT OF NEW ENTRANTS
FIGURE 07.MODERATE INTENSITY OF RIVALRY
FIGURE 08.IMPACT ANALYSIS: GLOBAL TOPICAL PAIN RELIEF MARKET
FIGURE 09.COMPARATIVE ANALYSIS OF TOPICAL NON-OPIOIDS MARKET, 2019 & 2027 ($MILLION)
FIGURE 10.NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET, 2019 & 2027 ($MILLION)
FIGURE 11.METHYL SALICYLATE MARKET, 2019 & 2027 ($MILLION)
FIGURE 12.CAPSAICIN MARKET, 2019 & 2027 ($MILLION)
FIGURE 13.LIDOCAINE MARKET, 2019 & 2027 ($MILLION)
FIGURE 14.OTHERS NON-OPIOIDS MARKET, 2019 & 2027 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF GLOBAL TOPICAL OPIOIDS MARKET, 2019 & 2027 ($MILLION)
FIGURE 16.BUPRENORPHINE MARKET, 2019 & 2027 ($MILLION)
FIGURE 17.FENTANYL MARKET, 2019 & 2027 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR CREAM, 2019 & 2027 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR GEL, 2019 & 2027 ($MILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR SPRAY, 2019 & 2027 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR PATCH, 2019 & 2027 ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR OTHERS, 2019 & 2027 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF PRESCRIPTION TOPICAL PAIN RELIEF MARKET, 2019 & 2027 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER TOPICAL PAIN RELIEF MARKET,
2019 & 2027 ($MILLION)
FIGURE 25.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR PHARMACIES & DRUG STORES,
2019 & 2027 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR E-COMMERCE,
2019 & 2027 ($MILLION)
FIGURE 27.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR REATIL & GROCERY SHOPS,
2019 & 2027 ($MILLION)
FIGURE 28.PERCENTAGE OF PEOPLE WITH DIFFERENT TYPES OF PAIN IN U.S., 2015
FIGURE 29.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 30.GSK: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 31.GSK: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 32.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 33.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 34.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 35.NESTL?: REVENUE, 2017–2019 ($MILLION)
FIGURE 36.NESTL?: REVENUE SHARE BY OPERATING SEGMENT, 2019 (%)
FIGURE 37.NESTL?.: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 38.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 39.NOVARTIS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 40.NOVARTIS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 41.PFIZER: NET SALES, 2017–2019 ($MILLION)225
FIGURE 42.PFIZER: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 43.PFIZER: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 44.RB: REVENUE, 2017–2019 ($MILLION)
FIGURE 45.RB: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 46.RB: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 47.SANOFI.: NET SALES, 2017–2019 ($MILLION)
FIGURE 48.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 49.SANOFI: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 50.SUN PHARMA: NET SALES, 2017–2019 ($MILLION)
FIGURE 51.SUN PHARMA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 52.SUN PHARMA: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 01.GLOBAL TOPICAL PAIN RELIEF MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04.HIGH BARGAINING POWER OF BUYERS
FIGURE 05.HIGH THREAT OF SUBSTITUTES
FIGURE 06.HIGH THREAT OF NEW ENTRANTS
FIGURE 07.MODERATE INTENSITY OF RIVALRY
FIGURE 08.IMPACT ANALYSIS: GLOBAL TOPICAL PAIN RELIEF MARKET
FIGURE 09.COMPARATIVE ANALYSIS OF TOPICAL NON-OPIOIDS MARKET, 2019 & 2027 ($MILLION)
FIGURE 10.NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET, 2019 & 2027 ($MILLION)
FIGURE 11.METHYL SALICYLATE MARKET, 2019 & 2027 ($MILLION)
FIGURE 12.CAPSAICIN MARKET, 2019 & 2027 ($MILLION)
FIGURE 13.LIDOCAINE MARKET, 2019 & 2027 ($MILLION)
FIGURE 14.OTHERS NON-OPIOIDS MARKET, 2019 & 2027 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF GLOBAL TOPICAL OPIOIDS MARKET, 2019 & 2027 ($MILLION)
FIGURE 16.BUPRENORPHINE MARKET, 2019 & 2027 ($MILLION)
FIGURE 17.FENTANYL MARKET, 2019 & 2027 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR CREAM, 2019 & 2027 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR GEL, 2019 & 2027 ($MILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR SPRAY, 2019 & 2027 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR PATCH, 2019 & 2027 ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR OTHERS, 2019 & 2027 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF PRESCRIPTION TOPICAL PAIN RELIEF MARKET, 2019 & 2027 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER TOPICAL PAIN RELIEF MARKET,
2019 & 2027 ($MILLION)
FIGURE 25.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR PHARMACIES & DRUG STORES,
2019 & 2027 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR E-COMMERCE,
2019 & 2027 ($MILLION)
FIGURE 27.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR REATIL & GROCERY SHOPS,
2019 & 2027 ($MILLION)
FIGURE 28.PERCENTAGE OF PEOPLE WITH DIFFERENT TYPES OF PAIN IN U.S., 2015
FIGURE 29.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 30.GSK: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 31.GSK: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 32.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 33.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 34.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 35.NESTL?: REVENUE, 2017–2019 ($MILLION)
FIGURE 36.NESTL?: REVENUE SHARE BY OPERATING SEGMENT, 2019 (%)
FIGURE 37.NESTL?.: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 38.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 39.NOVARTIS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 40.NOVARTIS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 41.PFIZER: NET SALES, 2017–2019 ($MILLION)225
FIGURE 42.PFIZER: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 43.PFIZER: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 44.RB: REVENUE, 2017–2019 ($MILLION)
FIGURE 45.RB: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 46.RB: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 47.SANOFI.: NET SALES, 2017–2019 ($MILLION)
FIGURE 48.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 49.SANOFI: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 50.SUN PHARMA: NET SALES, 2017–2019 ($MILLION)
FIGURE 51.SUN PHARMA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 52.SUN PHARMA: REVENUE SHARE BY REGION, 2019 (%)
